Wen-Chyi Shyu

CEO
​BRIM Biotechnology Inc.

With more than two decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and commercial expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in R&D ranges from pre-clinical and clinical drug metabolism to pharmacokinetic drug discovery, drug development, and life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab. Wen Chyi brings to BRIM extensive industry experience and a passion for driving drug discovery and development innovation. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee of the New England Drug Metabolism Discussion Working Group (NEDMDG) to identify and improve the drug discovery process and to shorten study turnaround time. Wen Chyi has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development. She has a passion for training, motivating, and developing research scientists to become successful pharmaceutical executives and has built numerous international and multi-disciplinary teams. Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.

Speech title & Synopsis

Managing a Robust Logistic System for Cell and Gene Therapies